Oncolytics Biotech Expands GI Tumor Scientific Advisory Board with Eileen O’Reilly, Neil Segal, and Van Morris

Oncolytics Biotech has expanded its *Gastrointestinal (GI) Tumor Scientific Advisory Board by appointing three globally recognized GI oncology experts:*
Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris.645

The GI Tumor Scientific Advisory Board was recently established to support Oncolytics’ growing portfolio of clinical programs in pancreatic, colorectal, and anal cancers and to guide strategy for developing pelareorep as a platform immunotherapy across GI tumors.643

With these additions, the GI SAB now comprises six experts from leading academic and clinical institutions across North America and Europe.46

The three new members are leading GI oncologists at top cancer centers and will contribute deep clinical and strategic expertise as Oncolytics advances late‑stage development of pelareorep and designs registration‑enabling trials in pancreatic, colorectal, and anal cancers.46

The GI SAB will continue to provide guidance on study design, clinical strategy, and translational initiatives to support Oncolytics’ programs as they move toward pivotal and potential registration studies.45

Oncolytics highlights pelareorep’s prior clinical data in GI cancers, including an aggregated analysis in first‑line pancreatic ductal adenocarcinoma showing a two‑year overall survival of ~22% with pelareorep‑based regimens versus a historical benchmark of ~9%.42

The company is planning pivotal studies in pancreatic, colorectal, and anal cancers and continues to engage with the U.S. FDA, aiming to position pelareorep as the first true platform immunotherapy in GI tumors.423

Sources:

2. https://www.investing.com/news/company-news/oncolytics-biotech-expands-gi-cancer-advisory-board-with-three-experts-93CH-4435169

3. https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-establishes-gastrointestinal-tumor-scientific-advisory-board-to-advance-pelareorep-as-a-platform-immunotherapy/

4. https://www.barchart.com/story/news/36927511/oncolytics-biotech-expands-its-gastrointestinal-tumor-scientific-advisory-board-with-the-addition-of-dr-eileen-oreilly-dr-neil-segal-and-dr-van-morris

5. https://www.marketscreener.com/news/oncolytics-biotech-inc-expands-scientific-advisory-board-with-the-appointment-of-eileen-o-reilly-n-ce7e59dcdf88f627

6. https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-expands-its-gastrointestinal-tumor-scientific-advisory-board-with-the-addition-of-dr-eileen-oreilly-dr-neil-segal-and-dr-van-morris/